Article
Overall survival analysis of patients enrolled in a randomized phase III trial comparing gefitinib and erlotinib for previously treated advanced lung adenocarcinoma (WJOG5108LFS).
International journal of clinical oncology - 1 Jan 2023
Katakami Nobuyuki, Yokoyama Toshihide, Morita Satoshi, Okamoto Tatsuro, Urata Yoshiko, Hattori Yoshihiro, Iwamoto Yasuo, Sato Yuki, Ikeda Norihiko, Takahashi Toshiaki, Daga Haruko, Oguri Tetsuya, Fujisaka Yasuhito, Nishino Kazumi, Sugawara Shunichi, Kozuki Toshiyuki, Oki Masahide, Yamamoto Nobuyuki, Nakagawa Kazuhiko
Abstract excerpt
BACKGROUND: Since the overall survival (OS) of patients enrolled in the first clinical phase III trial (WJOG5108L) was not recorded owing to time constraints, the present study (WJOG5108LFS) with a longer follow-up (66.6 months) aimed to compare OS of those treated with erlotinib (ER) and gefitinib (GE) for lung adenocarcinoma with epidermal growth factor receptor (EGFR) mutation. METHODS: Among 536 enrolled...
Topics
- Humans
- Gefitinib
- Erlotinib Hydrochloride
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Protein Kinase Inhibitors
- Quinazolines
- Adenocarcinoma of Lung